Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Quinapril and lipoic acid show benefit in metabolic syndrome

April 8, 2010

Galapagos identifies novel androgen receptor ligands

April 8, 2010

Warner Chilcott assumes full commercial responsibility for Actonel in U.S.

April 7, 2010

Teijin and Astellas to market TMX-67 for hyperuricemia in gout patients in China and Hong Kong

April 7, 2010

FDA's metabolic division deems Repros' phase II Androxal trial protocol adequate

April 7, 2010

Effects of dalcetrapib and pravastatin on lipoprotein profile determined in dyslipidemia

April 7, 2010

AMAG and Takeda enter into agreement to develop and market Feraheme

April 6, 2010

Orexigen submits NDA in U.S. for Contrave obesity treatment

April 6, 2010

Ardea reports phase IIb RDEA-594 monotherapy data in hyperuricemia and gout

April 6, 2010

Merck & Co. selects antiobesity CB1 inverse agonist MK-5596 as clinical candidate

April 6, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...